Pernix治療控股 PTXTQ 深 滬
等待開盤 09-18 09:30:00 美东时间
0.00
0.000
NaN.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 0.00
- 總市值 0
- 52周最高 0.00
- 市盈率 靜 --
- 換手率 NaN.00%
- 52周最低 0.00
- 委 比 0.00%
- 總股本 --
- 歷史最高 0.00
- 量 比 0
- 振 幅 NaN.00%
- 歷史最低 0.00
- 每 手 1
- 風險率
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Pelthos Therapeutics to Participate in the 2025 Wells Fargo Healthcare Conference
Pelthos Therapeutics Inc. announced that its CEO, Scott Plesha, and CFO, Frank Knuettel, will present at the Wells Fargo Healthcare Conference on September 3, 2025, at 1:30 p.m. ET. The presentation will be available via webcast on Pelthos' website, with an archive available for 90 days. Pelthos, a biopharmaceutical company, focuses on innovative therapeutic products, with its lead product, ZELSUVMI™, approved for molluscum contagiosum treatment.
09-02 12:00
Passage Bio to Participate in H.C. Wainwright 27th Annual Global Investment Conference
Passage Bio, a clinical-stage genetic medicines company focused on treating neurodegenerative diseases, announced it will participate in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, in New York City. CEO Will Chou will present an overview of the company, and a video webcast of the presentation will be available starting September 5, 2025. Passage Bio's lead product candidate, PBFT02, targets conditions l...
08-28 11:00
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
Phathom Pharmaceuticals announced that its management team will participate in two investor conferences in September: the Cantor Global Healthcare Conference on September 3-5 and the H.C. Wainwright Global Investment Conference on September 8-10. Details and webcast links are available on the company's website. Phathom focuses on developing treatments for gastrointestinal diseases, including vonoprazan for GERD and H. pylori.
08-25 11:59
Phathom Pharmaceuticals Clarifies That There Is No Reduction in Lead Shareholder’s Ownership Following Administrative Change to 13D Filing
Phathom Pharmaceuticals, Inc. clarified that Frazier Life Sciences' upcoming Schedule 13D filing, on August 20, will include administrative changes to its reporting approach but does not reflect a reduction in ownership by any Frazier fund or individual. The new filing may show a different breakdown of holdings and warrant treatment, but these changes are purely procedural and unrelated to share sales. Phathom is a biopharmaceutical company focus...
08-20 12:00
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results
Pliant Therapeutics has halted development of bexotegrast in idiopathic pulmonary fibrosis (IPF) following a safety and efficacy analysis. The company continues Phase 1 trials of PLN-101095 in solid tumors, expecting data by year-end. Restructuring efforts to reduce costs have largely been completed, with decreases in R&D and general expenses. As of June 2025, the company held $264.4 million in cash. Pliant remains focused on advancing integrin-b...
08-07 20:05
Plus Therapeutics Provides US Launch Update for its CNSide® Diagnostic
Houston-based Plus Therapeutics subsidiary CNSide Diagnostics will launch its CSF assay platform for detecting cancer metastases in the central nervous system in Texas in August 2025. The initial commercial focus will be on NCI-Designated Cancer Centers and large healthcare systems. The CNSide assay offers high sensitivity (92%) and specificity (95%), surpassing traditional CSF cytology methods. It has been used in over 11,000 tests since 2020 an...
07-31 11:30
Phathom Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide Business Update on Thursday, August 7, 2025
Phathom Pharmaceuticals将举行电话会议，于2025年8月7日上午8点EDT，讨论2025年第二季度财务结果及业务更新。会议直播及更多信息可访问公司官网https://investors.phathompharma.com/news-events/events-and-presentations。录音将保存90天。公司专注于胃肠道疾病治疗产品的研发与商业化，其核心产品为vonoprazan。
07-28 12:00
Plus Therapeutics Announces $1.6 Million Advance Payment from CPRIT
Plus Therapeutics has received a $1.6 million advance payment from the Cancer Prevention and Research Institute of Texas (CPRIT) as part of a $17.6 million grant to support its targeted radiotherapeutic development program for leptomeningeal cancer. The funding will accelerate the ReSPECT-LM clinical trial and further develop the CNSide LM diagnostic test. CPRIT, the second-largest public cancer research funder globally, joins the NIH and DoD in ...
07-23 11:30
Plus Therapeutics Announces FDA Agreement to Initiate ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases
Houston-based Plus Therapeutics has initiated the ReSPECT-LM dose optimization trial for REYOBIQ, targeting leptomeningeal metastases (LM). Building on Phase 1 results, the trial aims to determine optimal dosing regimens for maximum safety and efficacy, supported by a $17.6M CPRIT grant. Previously, the single-dose trial demonstrated a 76% clinical benefit rate and no dose-limiting toxicities in early cohorts. The ReSPECT-LM trial will enroll up ...
06-30 11:30
Palvella Therapeutics Added to Russell 3000® and Russell 2000® Indexes
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on treating serious, rare genetic skin diseases without FDA-approved therapies, has been added to the Russell 3000® and Russell 2000® indexes effective June 30, 2025. Membership in these indexes reflects the company's market capitalization and is part of the annual reconstitution process. Palvella is developing a pipeline of product candidates, including its lead QTOR...
06-30 11:30
